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Summary 
Immune complexes containing human gamma (g)l or murine g2a antibodies generate secondary 
erector mechanisms via Fc receptor binding or complement activation, whereas those containing 
human g4 or murine gl antibodies generally do not. Therefore, isotype selection of therapeutic 
antibodies may have important clinical  consequences. In a rabbit model of recombinant human 
tumor necrosis factor (rhuTNF)-induced pyrexia, a murine/human chimeric g4 anti-human TNF-ot 
mcnoclonal antibody (mAb) (cCB0011) showed a dose-dependent inhibition ofpyrexia, whereas 
a gl isotype variant of the same mAb gave a marked pyrexia that was seen at all doses indicative 
of an immune complex-mediated response. To investigate whether isotype difference could influence 
mAb efficacy in pathological  disease  states,  hamster/murine  chimeric gl  and g2a anti-murine 
TNF-o~  mAbs  (TN3gl,  TN3g2a)  were  studied  in  experimental  shock  in  mice  and  rats.  In 
lipopolysaccharide-induced  shock in mice, treatment with TN3gl mAb at 30 and 3 mg/kg resulted 
in 90% survival by 72 h 00 ~< 0.004),  and prolonged survival to 45 h  (p ~< 0.05),  respectively, 
compared with  100%  mortality by 27 h in controls.  In contrast,  a g2a isotype variant  of the 
same mAb (30 mg/kg) resulted in only 10% survival by 72 h (p ~< 0.05). In a neutropenic sepsis 
model in rats there was greater survival in animals receiving the gl isotype of TN3 compared 
with g2a isotype variant (70 vs. 27%; p ~< 0.005) with 100% mortality in the controls. These 
differences were not due to the pharmacokinetic profiles of the mAbs. In models of experimental 
shock antibody isotype can affect  outcome with  inactive isotypes (human  g4 and murine  gl) 
being more efficacious  than  active isotypes (human  gl  and murine  g2a). 
C 
linical septic shock continues to be associated with a high 
mortality rate,  despite the availability of potent broad 
spectrum antimicrobial  agents (1, 2). As a result, much in- 
terest has centered on additional therapeutic strategies that 
address the systemic inflammatory consequences of infection 
in the shocked patient. 
It is known that many of the features of septic shock are 
caused by endotoxin or LPS,  a component of bacterial cell 
walls (3-5). Endotoxin exerts many of its effects indirectly 
by triggering the release of a complex cascade of endogenous 
mediators.  It is the effect of these mediators on the tissues 
that  elicits the clinical  symptoms of septic shock. 
This paper was presented in part at the British Pharmacological Society 
Meeting, Bradford, UK, July 1993. 
TNF  has  been  identified  as  a  major  proinflammatory 
cytokine synthesized primarily by macrophages/monocytes 
but also by other activated cells such as lymphocytes, natural 
killer cells, and endothelium (5-7).  It can be stimulated by 
a wide variety of infectious or inflammatory stimuli (8, 9), 
and  will  itself trigger  the  release  of other  inflammatory 
cytokines,  such as IL-1  and IL-6. 
TNF  is  one of the  principal  cytokines  involved in  the 
pathology of septic shock.  When  administered  to animals 
and humans TNF causes hemodynamic and pathophysiolog- 
ical symptoms that resemble the responses to endotoxemia 
(4, 10-12). In addition, controlled administration of LPS into 
human volunteers leads to a rapid rise in serum levels of TNF 
(13), and in some sepsis and septic shock diseases TNF levels 
are elevated (9,  14,  15).  Indeed, anti-TNF  immunotherapy 
using either polyclonal antibodies or mAbs has been shown 
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travenous doses of Escherichia coli in animal models (16-18). 
These results form the basis for an immunotherapy strategy 
for treating septic shock in humans with antibodies against 
TNF for which the selection of the most appropriate and 
effective antibodies is of paramount importance. 
Although studies using animal models have focused on the 
feasibility of using anti-TNF mAb immunotherapy either 
alone or in combination with known treatments, none has 
addressed the question of the effect of isotype on the efficacy 
of an antibody. The antibody isotype (Fc region) is known 
to determine the ability of antibody/antigen complexes to 
direct immune responses,  for example, by initiating the com- 
plement cascade or interacting with Fc receptors on cells of 
the reticuloendothelial system (19-22). Therefore the efficacy 
of an antibody may be directly related to its Fc function. Im- 
mune complexes containing human  gammal  (gl) 1 or mu- 
rine gamma2a (g2a) antibody isotypes are efficient at binding 
Clq and hence initiating the complement cascade.  In addi- 
tion, they interact with and activate Fc receptors on cells such 
as macrophages, neutrophils,  and lymphocytes (21-24).  In 
contrast, immune complexes containing human gamma4 (g4) 
or murine gammal  (gl) antibody isotypes do not bind to 
Fc receptors and Clq effectively.  Therefore these antibody 
isotypes do not mediate clearance of antigen by activating 
components of the reticuloendothelial system, but neutralize 
the antigen by forming antigen-antibody complexes. 
The effect of human gl  and g4 isotypes on the efficacy 
of an anti-human TNF (cCB0011) mAb was initially studied 
in a rabbit model of recombinant human TNF (rhuTNF)- 
induced pyrexia using  murine/human  chimeric anti-TNF 
mAbs. This study indicates that different isotypes can modify 
the pyrexia seen. Furthermore, to determine whether isotype 
difference can influence therapeutic outcome, hamster/murine 
chimeric anti-murine TNF mAbs were made by replacing 
the entire constant regions of the heavy and light chains of 
hamster mAb,  TN3-19.12 (25), with either murine gl  or 
g2a constant regions. The relative protective efficacy of these 
antibodies was compared in a LPS-induced shock model in 
mice, and in a model of Pseudomonas aeruginosa bacteremia 
in immunocompromised rats. 
Materials  and Methods 
rhuTNF-induced Pyrexia Model in Rabbits 
Dose-Reswnse Curve.  Male  NZW rabbits (18-22 kg) (Kosemead 
Rabbits, Waltham Abbey, UK) were placed in restraining stocks 
and a temperature thermistor probe was inserted ,,04 cm into the 
rectum.  Kectal temperature  was recorded every 5 min using an 
Isothermex monitoring device (Columbus Instruments, Columbus, 
OH). Drugs were administered via the femoral vein and blood 
samples withdrawn via the femoral artery, both vessels having been 
cannulated 24 h previously. After a 60-rain stabilization, rabbits 
were given one of the following pretreatments:  (a) saline only 
(n = 4); (b) cCB0011gl, 1-100/,g/kg (n = 4-5); and (c) cCB0011g4, 
1-100/*g/kg (n = 4-7). This was followed 15 min later by 1/~g/kg 
1  Abbreviations  used in thispaper: gl, gamma1; g2a, gamma2a; g4, gamma4; 
rhu, recombinant human. 
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rhuTNF (Saxon Biochemical Gmbh, Hanover, Germany). Saline- 
saline, cCB0011g1 (100/~g/kg)-saline, and cCB0011g4 (100/~g/kg)- 
saline groups served as controls (n  =  3-4). Blood samples were 
taken every 60 min up to 5 h for plasma rhuTNF  measurement 
by ELISA (26) and L929 assay (27), after which the animals were 
killed. 
Effect of Preformed Immune Complexes.  In two further groups 
of rabbits (n  =  6 per group), preformed TNF/anti-TNF  immune 
complexes were administered via the femoral vein and measure- 
ments continued for 300 min. One group received  cCB0011g1 (100 
t~g/kg)/rhuTNF (1 #g/kg) and the other received  cCB0011g4 (100 
/xg/kg)/rhuTNF (1/~g/kg) immune complexes. The antibodies and 
rhuTNF were mixed and allowed to stand for 60 rain before ad- 
ministration. 
LPS-induced Shock Model in Mice.  Male  BALB/c mice (18-20 g) 
(Harlan Olac Ltd., Bicester, UK) were housed in a thermoneutral 
environment with a 12-h light/dark cycle, and allowed to eat and 
drink  ad libitum. 
LPS (Serotype 0111.B4; Sigma Chemicals Ltd., Poole, UK) was 
freshly prepared to the required concentration before the start of 
the experiment by dilution in sterile saline. In a pilot study, a LPS 
dose of 5 mg/kg caused 100% mortality within 48 h and was chosen 
for further experiments. 
For investigation into the effect of mAb treatment,  groups of 
10 mice were anaesthetized using halothane in 5% O5 1 h before 
receiving LPS, and injected with either 0.15 ml (i.v.) saline or 0.15 
ml (i.v.) of TN3gl or TN3g2a, then allowed to recover. The anti- 
bodies were used at doses of 30, 3, and 0.3 mg/kg. I h later (time 
0) the animals were reanesthetized and received either 0.1 ml of 
saline or 0.1 ml of LPS (50 mg/kg i.v.). Animals were assessed 
at least four times daily and surviving animals were killed after 72 h. 
In  a separate experiment,  groups  of 10 mice received either 
MOPC21 (30 mg/kg) or TALl4.1 (30 mg/kg) 1 h before LPS chal- 
lenge. These antibodies served as nonspecific antibody controls for 
TN3gl and TN3g2a, respectively. 
Neutrownic Rat Sepsis Model.  Female, albino, pathogen-free 
Sprague-Dawley rats (Charles River Breeding Laboratories, Wil- 
mington, MA) weighing  125-150 g were maintained in filtered 
biosafety cages and allowed to eat and drink ad libitum. Animals 
were pretreated with intramuscular cefamandole (Eli Lilly, Indi- 
anapolis, IN) at 100 mg/kg on an every other day schedule, and 
then rendered neutropenic by intraperitoneal administration of cy- 
clophosphamide (Bristol-Myers, Evansville, IN) at a dose of 150 
mg/kg at time 0 followed by a second dose of 50 mg/kg 72 h later. 
The details of this animal model have  been described  previously  (28). 
Animals were inoculated orally with "~106 P. aeruginosa strain 
12.4.4 at 0, 48, and 96 h after the initial dose ofcyclophosphamide. 
At the onset of fever, antibody therapy with either TN3gl (n  = 
20), TN3g2a (n  =  22), or control mAb (L23D9; Celltech Ltd., 
Slough, UK) (n  =  18) was given at 20 mg (i.v.). Blood cultures 
and serum specimens for endotoxin and TNF levels were obtained 
at onset of fever  and 24 h after onset of fever  in each animal. Endo- 
toxin levels were measured by a quantitative turbidimetfic Limulus 
lysate method (Associates of Cape Cod, Inc., Woods Hole, MA), 
and bioactive circulating TNF levels were measured by the L929 
bioassay (27). Animals were examined daily for a 12-d period and 
all animals that did not survive  the study period underwent necropsy 
examination with quantitative bacterial  cultures of  liver, lung, heart, 
and spleen tissue. 
Monoclonal Antibodies 
Chimeric Anti-murine  TNF-ol mAb (TN3).  TN3  is  a  mu- 
fine/hamster chimeric anti-murine TNF-cr with hamster variable 
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ther gl (TN3gl) or g2a (TN3g2a) isotype, cDNA clones containing 
genes for the heavy and light chains of the hamster antibody, TN3- 
19.12 (25), were isolated (29, 30). Chimeric (hamster-mouse) genes 
were constructed joining the hamster V1 gene to mouse Ck and 
the hamster Vh gene either to mouse C-gamma1 (gl) or mouse 
C-gamma2a (g2a) (31, 32). These chimeric genes were subcloned 
for expression  and cell lines established by transfecting linearized 
plasmid DNA into NSO cells and selecting cells that grew in the 
absence of glutamine (33).  The hamster/murine chimeric mAbs 
(TN3g2a  and  TN3gl)  were purified  from  100  liters  of tissue 
culture supernatant  by protein  A  affinity chromatography and 
shown to be >98% monomeric IgG by HPLC on a Zorbax GF250 
size exclusion column (DuPont, Wilmington, DE) and reducing 
and  nonreducing  SDS-PAGE  (34).  Endotoxin  levels  were  <2 
IU/mg (35). 
In vitro bioassay, using the L929 mouse fibroblast assay (27), 
showed that both mAbs were equipotent to hamster TN3-19.12 (25). 
Nonspecific Control mAbs.  TALl4.1 is a murine g2a mAb directed 
against HLA-DRo~ (Imperial Cancer Research Fund, London, UK) 
(36). MOPC21 is a murine gl mAb derived from X63P3 with no 
known specificity. L23D9 is a hamster-derived mAb directed against 
murine recombinant IL-2 that does not react with natural murine 
or rat IL-2 (25).  Endotoxin levels were <0.1  IU/ml. 
Chimeric Anti-human TNF-oL mAb (cCBO011).  cCB0011  is a mu- 
fine/human chimeric anti-human  TNF-c~ with murine variable 
regions and human constant regions of either gl (cCB0011gl)  or 
g4 (cCB0011g4) isotype. The antibodies were prepared as described 
above from murine anti-human TNF-o~ mAb, 101/4 (National In- 
stitute of Biological Standards  and Control, London, UK). Endo- 
toxin levels were <0.7 IU/mg. 
Pharmacokinetics of Chimeric Anti-murine TNF mAb and Deter- 
mination of  Immune Response to Antibodies.  Groups of male BALB/c 
mice (Harlan Olac Ltd.) (n  =  4-5) received  10 mg/kg (i.p.)  of 
antibody with serum samples obtained at 0, 8, and 24 h, 3, 6, 7, 
10, 13, 14, 17, 20,  and 21 d. Groups of male Lewis rats (Harlan 
Olac Ltd.) (n =  3) received 10 mg/kg (i.p.) of antibody with plasma 
samples taken at 0, 8, and 24 h, and 3, 4, 6, 7, 8, 10, 13, 16, 19, 
and 21 d. 
Serum or plasma concentrations of TN3gl and TN3g2a were 
measured using an ELISA. Plates were coated with rabbit anti-TN3- 
19.12 antibody at 2.5/~g/ml. Samples were serially diluted and as- 
sayed in duplicate with the relevant isotype standard in each assay. 
A  biotin-conjugated  antibody  to  the  hypervariable  regions  of 
TN3-19.12 (rabbit anti-cTN3-19.12  g2a affinity purified on TN3- 
19.12-Sepharose) was then added,  and the assay completed with 
horseradish  peroxidase-streptavidin  (HRP-SA)  followed  by 
tetramethylbenzidine (TMB) substrate. 
A specific double-antigen sandwich ELISA was used to detect 
immune responses. Plates were coated with the TN3-19.12 isotype 
under investigation at 1/zg/ml.  Isotype-specific,  affinity-purified 
rabbit polyclonal standards  were used.  Samples were diluted 1:10 
and assayed in duplicate.  Biotin-conjugated TN3-19.12 (same iso- 
type) was then added,  followed by HRP-SA and TMB substrate. 
Results were expressed as U/ml, where 1 U is equivalent to 1 #g/ml 
rabbit anti-TN3-19.12. 
Data Analysis.  For the rabbit pyrexia model differences between 
groups were assessed by one-way analysis of variance (ANOVA). 
Differences were considered significant  when/~ <0.05. Statistical 
analysis of the Kaplan-Meier survival curves from the LPS-induced 
shock model in mice was performed using the log-rank test and 
the Wilcoxin test. Differences were considered significant  when 
p <0.004, and borderline significant when p <0.05. Kruskel-Wallis 
one-way ANOVA was used to analyze the survival of animals in 
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the neutropenic rat model. Differences were considered significant 
when p <0.05. 
Results 
Effect of Chimeric Anti-human  TNF (gl  and g4) mAb 
on rhuTNF-induced Pyrexia  in Rabbits 
Dose-Response Curve  to  rhuTNE  None  of  the  control 
groups showed any rise in temperature during the experimental 
period.  In the saline plus rhuTNF-treated group there was 
a transient rise in rectal temperature with a peak of +0.69  __ 
0.1~  at 60 rain.  In the presence of cCB0011g4 mAb there 
was  a  dose-dependent  inhibition  of the  rhuTNF-induced 
pyrexia, the pyrexia being completely ablated by 100/~g/kg 
of antibody  (Fig.  1 A). 
With the gl isotype, however, a marked pyrexia was seen 
at all doses.  Indeed, with the lowest dose of antibody,  the 
pyrexia was greater than that seen in the saline plus rhuTNF 
group (Fig. 1 B). Furthermore, there was a persistent pyrexia 
in the highest dose group (100/~g/kg)  plus rhuTNF with 
the temperature remaining raised until the end of the experi- 
ment  (5  h). 
In contrast to the pyrexia data, the effect of both isotypes 
on the removal of rhuTNF from the plasma was the same. 
Both gave a dose-dependent reduction in immunoreactive and 
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Figure  1.  Effect  of different isotypes of cCB0011 mAb on rhuTNF- 
induced pyrcxia in rabbits. (A) cCB0011g4 (n  =  4-7); (B) cCB0011gl 
(n  =  4-5).  Data  are mean  -+  SEM. A  lO 
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Figure  2.  Dose-dependent  reduction in immunoreactive rhuTNF in 
plasma. (A) cCB0011g4; (B) cCB0011gl. Data are geometric mean and 
95% confidence interval (C.I.). 
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Figure  3.  Effect  of preformed  immune  complexes  of cCB001tgl  and 
g4 plus  rhuTNF  on pyrexia in rabbits  (n  =  6).  Data are mean  _+  SEM. 
Treatment with 30 mg/kg TN3gl  antibody gave a sur- 
vival probability of 90%  by 72 h, which was significantly 
different  from the saline-treated controls (p <0.004)  (Fig. 4 
B).  In addition,  there  was prolongation of survival to 45 h 
in the animals treated with 3 mg/kg cTN3-19.12 gl (p <:0.05). 
No protection against LPS-induced shock was seen with the 
0.3-mg/kg  antibody  dose with  100%  mortality by 27 h. 
Statistical comparison of the two antibodies at the highest 
antibody dose (30 mg/kg) showed that there was a significant 
benefit (p <0.004) to using TN3gl compared with TN3g2a. 
Effect of Chimeric Anti-murine  TNF mAb on Neutropenic 
Rat Sepsis  Model.  Bacteremic infection with challenge strains 
ofP. aeruginosa  was observed in 18/18 control animals, 21/22 
TN3g2a-treated animals, and 19/20 TN3gl-treated animals. 
A 
bioactive rhuTNF in the plasma with none being detected  .~ 
at  either  10 or  100 #g/kg  of each  antibody  (Fig.  2). 
Effect of Preformed Immune Complexes.  With  preformed 
immune  complexes  of cCB0011g4/rhuTNF  there  was  no  -~ 
change in temperature during the course of the experiment.  .-~ 
In the case of cCB0011g1/rhuTNF immune complexes, there  g 
was an initial rise in temperature followed by a further progres- 
sive rise,  reaching  +0.5  _+  0.2~  by 5  h  (Fig.  3).  At  the 
end  of  the  experiment,  the  change  in  temperature  was 
significantly higher (2 <0.05) in the gl compared with the 
g4 immune complex-treated group. No free bioactive TNF  B 
was detectable in either preparation of immune complexes. 
Effect of Chimeric Anti-murine TNF mAb on LPS-induced 
Shock in Mice.  All animals receiving saline only survived the 
duration of the experiment. In contrast, all saline-treated  con- 
o.  trol animals receiving LPS had died by 27 h, with overt symp-  _ 
toms of shock such as piloerection,  hunched posture, mor-  .~ 
bidity, and listlessness appearing by 6-8 h after LPS challenge. 
Pretreatment  with  nonspecific  control mAb  (MOPC21  or 
TALl4.1)  had no effect  on survival. 
TN3g2a antibody at 30 mg/kg  gave minimal protection 
with 10% survival at 72 h (p <0.05)  (Fig. 4 A).  No protec- 
tion was  seen with 3  mg/kg  (100%  mortality by 25.5  h) 
or 0.3  mg/kg  (100%  mortality by 21  h). 
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Figure  4.  Effect of different isotypes of TN3 mAb on survival after 
LPS-induced shock in mice. (A) TN3g2a (n =  10); (B) TN3gl (n = 10). 
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of  bacteremia when compared with animals receiving the con- 
trol mAb. Necropsy examination of animals that did not sur- 
vive the 12-d study period uniformly revealed multiorgan in- 
fection with P. aeruginosa 12.4.4. This finding was not affected 
by the administration  of anti-TNF mAb.  Serum bioactive 
TNF levels were not detectable by the L929 assay after ad- 
ministration of either TN3 mAbs.  Control animals had a 
mean of 2.25  _+  2.2 IU/ml of TNF detected in serum after 
administration of the control mAb (p <0.0001). Circulating 
endotoxin levels were comparable in septic animals regard- 
less of the mAb treatment received  (1.18 _+ 1.17 ng/ml TN3gl; 
1.35  _+  1.1 ng/ml TN3g2a; 1.36 _+  1.4 ng/ml control; not 
significant). 
Despite similar levels of  bacteraemia, circulating TNF levels, 
and endotoxin levels, animals that received TN3gl mAb had 
a significantly greater survival rate than animals that received 
TN3g2a mAb (70 vs. 27% survival;  p <0.005). TN3g2a mAb 
offered marginal survival benefit over the control group (27 
vs. 0% survival; p <0.05). The g2a isotype was clearly not 
as efficacious as the gl isotype  (Fig. 5). 
Pharrnacokinetics of Anti-TNF Antibodies.  In mice,  the 
Cm~x'S for 10 mg/kg chimeric TN3 mAbs were similar; 75 
/zg/ml for gl and 87 #g/ml for the g2a (Fig. 6). The elimi- 
nation phase half-life of both mAbs in the circulation was 
also similar at 9.3 d calculated from the peak of concentra- 
tion to the final value at 21 d. No measurable immune re- 
sponse was made against the antibodies by the mice from 
days 6 to 21. 
In rats, the Cmax'S for the mAbs were similar; 40.6 #g/ml 
for gl and 71.3/zg/ml for g2a with a steady elimination phase 
to day 10, after which clearance was more rapid (Fig. 7). The 
elimination phase half-life calculated to day 8 for TN3gl was 
5.4 d, and for TN3g2a was 6.1 d. The difference in half-life 
between the gl and g2a isotypes was not significant. The 
rapid clearance after day 10 coincided with the development 
of a measurable immune response (20 ng/ml) against the g2a 
isotype detectable from day 6,  though none was detected 
against the gl isotype. 
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Figure  6.  Pharmacokinetic profiles of TN3gl  and g2a in mice (n  = 
4-5).  Data  are geometric mean and 95%  C.I. 
Discussion 
In this study, we have investigated the effect of isotypes 
by making two matched pairs of antibodies. One pair uses 
human gl and g4 constant domains with an anti-human TNF 
binding site, and the second pair uses murine gl and g2a con- 
stant domains with an anti-murine TNF binding site. In terms 
of Fc effector function, the human gl and murine g2a are 
similar, both having the capacity to actively elicit immune 
responses via complement and Fc receptors. The human g4 
is matched to the murine gl in being functionally relatively 
inactive (22-24).  In both cases, each member of the pair has 
the same TNF neutralizing activity in vitro. For the murine 
pair, the plasma clearance rates have been shown to be similar 
in both mice and rats. 
Against this background, the effect of isotype differences 
on therapeutic efficacy  was studied in a series of animal shock 
models in which anti-TNF therapy had previously  been shown 
to  be  effective (16, 25,  37,  38).  The  human antibodies 
(cCB0011gl and cCB0011g4) were tested in a model of  rabbit 
pyrexia  induced by exogenous rhuTNF. The murine antibodies 
(TN3gl and TN3g2a) were tested in a murine lethal LPS 
challenge model and a model of Pseudomonas bacteremia in 
neutropenic rats. 
In the rabbit pyrexia model exogenous rhuTNF induced 
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Figure  5.  Effect of different isotypes of TN3 mAb on survival in neu- 
tropenic rat model. TN3gl (n =  20), TN3g2a (n =  22), control (n =  18). 
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Figure  7.  Pharmacokinetic profiles of TN3gl and g2a in rats (n  =  3). 
Data  are geometric mean and 95%  C.I. a rise in temperature.  This was inhibited,  as expected, in a 
dose-dependent manner by cCB0011g4. However, in the pres- 
ence of the gl isotype pyrexia was seen at all doses, despite 
the equal ability of both isotypes to reduce the plasma con- 
centration of the rhuTNF.  Indeed,  under gl treatment the 
pyrexia appeared to be slightly delayed and potentiated.  Fur- 
thermore, TNF/anti-TNF immune complexes preformed at 
ratios  sufficient to neutralize  all rhuTNF,  elicited a rise in 
temperature with complexes of gl but not g4 isotype. These 
data indicate that, in addition to neutralizing the TNF bio- 
activity, the human gl isotype containing immune complexes 
elicits other physiological effects, presumably via Fc receptor 
binding and/or complement fixation.  It was important to 
determine whether these effects of isotype difference could 
affect treatment efficacy in a pathological  situation.  To this 
end, hamster/murine chimeric mAbs were compared in le- 
thal models of septic shock in mice and rats. 
The murine gl mAb isotype effectively protected mice 
against the lethal effects of LPS challenge with 90% survival 
at 72 h compared with 100% mortality in the untreated con- 
trols. In contrast the murine g2a isotype gave only minimal 
protection against lethality with 10%  survival by 72 h in 
the high dose (30 mg/kg) antibody-treated group only. The 
superior effect of TN3gl observed in the endotoxin treated 
mice was confirmed in an infection model of Pseudomonas 
bacteremia in immunocompromised rats, where the differential 
effects of the two mAbs were not related to their ability to 
remove TNF from the circulation  of infected animals. In- 
deed both mAbs successfully neutralized bioactive TNF in 
the circulation  of neutropenic rats. 
These differences could be due to differing pharmacoki- 
netic profiles in vivo. However, TN3gl and TN3g2a have 
similar half-lives in the circulation of between 5-8 d in rats 
and 9 d in mice, indicating that accelerated clearance does 
not account for the lack of effect of the murine g2a antibody. 
In mice no immune response against the antibodies was de- 
tected that could have led to decreased efficacy.  Although an 
immune response was detected in rats from day 6, it is un- 
likely to have had an effect on efficacy  since most of the deaths 
in this model occurred within 6 days of antibody treatment. 
These results suggest that the Fc region of each antibody 
directly  influences  its  ability  to  prevent  TNF-mediated 
pathology. Kipps et al. (39) have demonstrated that the iso- 
type of murine antibodies will affect their ability to imple- 
ment antibody-dependent, ceU-mediated  cytotoxicity (ADCC) 
by human peripheral  blood lymphocytes.  They compared 
IgG1, IgG2a, and IgG2b antibody isotypes and showed that 
the murine IgG2a was most effective at mediating ADCC, 
with IgG2b being intermediate and IgG1 inactive. In addi- 
tion, Oi et al. (40) demonstrated that the capacity to fix com- 
plements was greatest for IgG2b, intermediate for IgG2a, and 
least for IgG1. Taken together,  this suggests that immune 
complexes containing the g2a antibody isotype may be ex- 
acerbating the symptoms of septic shock by activating com- 
plement and effector cells through their C3b or Fc receptors. 
This activation causes the release of additional inflammatory 
cytokines such as IL-6, IL-1, and TNF, which in turn poten- 
tiate the effects of TNF. In a model system where most of 
the pathological and hemodynamic  changes are occurring sys- 
temically, further activation of the immune and inflamma- 
tory networks may offset any beneficial effects of anti-TNF 
treatment and lead to reduced survival. Certainly at low dose 
(0.3 mg/kg), the g2a antibody isotype showed 100% mor- 
tality by 21 h compared with 27 h in the untreated controls 
in the LPS-induced shock model.  However, when used at 
sufficiently high doses the benefits of anti-TNF therapy may 
outweigh  the  negative  effects mediated  by  antibody  Fc 
function. 
This study clearly demonstrates  the importance of anti- 
body isotype on the functional antagonism of circulating TNF. 
In septic shock models, where systemic inflammatory reac- 
tions are occurring, an antibody that does not lead to further 
potentiation of the inflammatory network (i.e., murine gl 
and human g4) is more effective than an antibody capable 
of fixing complements and interacting with Fc receptors (i.e., 
murine g2a and human gl). Clearly an understanding of the 
interactions between different isotypes and effector mecha- 
nisms of the immune system will aid in choosing the best 
strategy for immunotherapy in various human diseases. 
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